




# PHARMACEUTICAL 2018

Regen BioPharma Inc  
Rank 330 of 342





# PHARMACEUTICAL 2018

Regen BioPharma Inc  
Rank 330 of 342

The relative strengths and weaknesses of Regen BioPharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen BioPharma Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 122% points. The greatest weakness of Regen BioPharma Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 259% points.

The company's Economic Capital Ratio, given in the ranking table, is -414%, being 460% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	478
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,863
Liabilities, Non-Current	0
Other Assets	466
Other Compr. Net Income	168
Other Expenses	649
Other Liabilities	332
Other Net Income	-3,328
Other Revenues	110
Property and Equipment	0
Research and Development	1,150
Selling, General and Administrative Expense	822

Output Variable	Value in 1000 USD
Assets	944
Liabilities	6,196
Expenses	2,621
Revenues	110
Stockholders Equity	-5,251
Net Income	-5,839
Comprehensive Net Income	-5,755
Economic Capital Ratio	-414%